DOG:ARCA-ProShares Short Dow30

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 52.75

Change

+0.51 (+0.98)%

Market Cap

USD 0.31B

Volume

0.29M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to the inverse (-1x) of the daily performance of the Dow Jones Industrial AverageSM. The fund invests in derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as the inverse (-1x) of the daily return of the index. The index is a price-weighted index and includes 30 large-cap, "blue-chip" U.S. stocks, excluding utility and transportation companies. The fund is non-diversified.

Inception Date: 19/06/2006

Primary Benchmark: DJ Industrial Average TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 0.97%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-18 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SCYB Schwab Strategic Trust 0.00 %

+0.02 (+0.04%)

N/A

ETFs Containing DOG

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.00% 26% F 12% F
Dividend Return 1.00% 71% C- 20% F
Total Return -13.00% 26% F 12% F
Trailing 12 Months  
Capital Gain -7.57% 34% F 28% F
Dividend Return 1.41% 68% D+ 25% F
Total Return -6.16% 34% F 27% F
Trailing 5 Years  
Capital Gain -48.47% 29% F 15% F
Dividend Return 1.14% 33% F 5% F
Total Return -47.33% 29% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain -11.80% 24% F 10% F
Dividend Return -11.50% 24% F 8% B-
Total Return 0.30% 24% F 8% B-
Risk Return Profile  
Volatility (Standard Deviation) 7.95% 92% A 80% B-
Risk Adjusted Return -144.75% 11% F 1% F
Market Capitalization 0.31B 87% B+ 32% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.